BridgeBio Presents New Phase 3 ATTRibute-CM Analyses And Real-World Evidence For Acoramidis In Transthyretin Amyloid Cardiomyopathy, At AHA Scientific Sessions 2026 And XX ISA 2026

Benzinga · 1d ago
  • In real-world German data from the Bayer-led mODIficATTR study, acoramidis was associated with a 23% lower risk of ODI, an early marker of worsening HF, versus tafamidis (adjusted HR 0.77; 95% CI 0.61–0.98; p=0.04), building on consistent results from the Wright et al. Komodo claims analysis (34% reduction in clinical worsening events; p=0.046) and the independently conducted Lanfear et al. Epic COSMOS electronic health record (EHR) study (27% lower risk of cardiovascular hospitalization; p<0.001)
  • This is also consistent with the ATTRibute-CM trial, in which acoramidis reduced the risk of a first HF-specific event by 45% versus placebo (HR 0.55; 95% CI 0.44–0.69; p<0.001) with benefit emerging within the first month of treatment
  • Benefit extended to every type of HF event with fewer HF deaths, HF hospitalizations, and outpatient worsening HF events for acoramidis versus placebo, and directionally consistent results across all prespecified subgroups
  • Continuous acoramidis was associated with a durable reduction in HF mortality through 54 months (HR 0.42; 95% CI 0.27–0.65; p<0.001)
  • Series of six kidney analyses of ATTRibute-CM indicated that acoramidis’ early eGFR dip associated with potentially rapid kidney-protective activity was: (i) consistently observed irrespective of baseline AF status, diabetes status, RAAS inhibitor use, and genotype with favorable clinical outcomes observed through Month 30 across all of these subgroups, (ii) not accompanied by any negative, clinically meaningful changes in laboratory measures or blood pressure, and (iii) did not lead to clinically meaningful changes in markers of kidney safety in participants with CKD stage 4, whose kidney function remained stable over 30 months
  • Real-world treatment patterns indicate that TTR stabilizers remain the predominant first-line therapy of choice for ATTR-CM with 81.4% of newly treated patients initiating TTR stabilizer monotherapy
  • Together, these data reinforce the speed and breadth of acoramidis' benefit on the outcomes that matter most to people living with ATTR-CM

PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, and the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay. At AHA 2026, BridgeBio had 2 moderated posters and 3 posters, and at ISA 2026, BridgeBio had 28 total abstracts accepted comprising 12 new poster presentations and 16 encore poster presentations. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

At AHA 2026, a new ATTRibute-CM analysis presented by Mazen Hanna, M.D. of Cleveland Clinic, U.S. showed that acoramidis reduced heart failure (HF) events quickly and across the board.